Tests AZD0120 cell therapy after standard treatment in adults with newly diagnosed multiple myeloma
Tests AZD0120 cell therapy in adults with newly diagnosed multiple myeloma.
Plain-language title generated from the registry record
Registry title: Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Key facts
- Where
- Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, and Suita-shi, JapanSee the 8 sites
- Phase
- Phase 3
Where in Japan
- FukuokaFukuoka, JapanNot yet recruiting
- KyotoKyoto, JapanNot yet recruiting
- Nishinomiya-shiNishinomiya-shi, JapanNot yet recruiting
- OkayamaOkayama, JapanNot yet recruiting
- SapporoSapporo, JapanNot yet recruiting
- Shibuya-kuShibuya-ku, JapanNot yet recruiting
- Shinjuku-kuShinjuku-ku, JapanNot yet recruiting
- Suita-shiSuita-shi, JapanNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07764978
- Record updated
- 14 August 2026
- Original description
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.Read full original descriptionShow less
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.
Inclusion: Participants must be 18 years or older, at the time of signing the ICF; Participant must have documented diagnosis of MM according to the IMWG diagnostic criteria; Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c)Serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda FLC ratio; Participant must be deemed ineligible for ASCT while also having adequate organ function for CAR-T cell treatment; Participant is a candidate to receive at least one of the regimens (IsaVRd or DRd) as determined by the Investigator; ECOG performance status Grade of 0 to 2; Participant must have adequate organ and bone marrow function.
Exclusion: Participant has active or prior CNS or meningeal involvement of MM; Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years; Participant has primary amyloidosis, active plasma cell leukemia (≥5% circulating plasma cells), Waldenström macroglobulinemia, or POEMS syndrome; Participant has significant neurological or psychiatric condition posing risk or impairing evaluation; Participant has any other significant medical condition that increases unacceptable risk, interferes with therapy delivery, or confounds evaluation; Participant has a history of haematologic malignancies, other than MM, regardless of remission status; Participant is positive for any of the following:; HIV: Known to be seropositive for HIV (including any history of HIV); Chronic or active hepatitis B; Active hepatitis C: Hepatitis C infection; Additional local requirements for the testing for infectious diseases and exclusions of applicable participants should be followed per local regulations; Participant has clinically significant cardiovascular disease; Participant has COPD with an FEV1 < 50% of predicted normal; Additional exclusion for participants who are planned to receive IsaVRd as induction: Participant has peripheral neuropathy Grade 4, Grade 3, Grade 2, or Grade 1 with pain.